Clinical trials: Pulmonary Hypertension (PH)
Pulmonary Arterial Hypertension (PAH)
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH).
- Trial name
- ILLUMINATE (NCT07318597)
- Testing
- REGN13335
- Where
- 33 sites in United States, Australia and 8 more
- Volunteers
- 99 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Thromboembolic Disease
BPA in CTEPD Without PH
The goal of this clinical trial is to assess the effect of Balloon Pulmonary Angioplasty (BPA) on quality of life and exercise capacity in patients with chronic tromboembolic pulmonary disease (CTEPD) without pulmonary…
- Trial name
- BALLOON (NCT06090838)
- Testing
- Balloon Pulmonary Angioplasty (BPA)
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Amsterdam UMC, location VUmc
Pulmonary Hypertension
Pulmonary Hypertension (PH) Biorepository for Translational Research
Background: Pulmonary hypertension (PH) is high blood pressure in the blood vessels of the lungs. It can lead to heart failure and death if not treated.
- Trial name
- NCT07647549
- Where
- 3 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)
COMPERA / COMPERA-KIDS
In view of the manifold options for mono- and combination therapy that have now emerged for patients with pulmonary (arterial) hypertension (PH/PAH), controlled clinical trials can only provide part of the information needed for…
- Trial name
- COMPERA (NCT01347216)
- Where
- 7 sites in Belgium, Germany and 2 more
- Volunteers
- 14,000 people
- Sponsor
- Technische Universität Dresden
Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Incorporating the Venous Excess Ultrasound Score (VExUS Score) Into Contemporary Haemodynamic Risk Assessment in Pulmonary Arterial Hypertension: The INVEXUS-PAH Study
This prospective observational study aims to evaluate the relationship between the Venous Excess Ultrasound Score (VEXUS) and the ESC/ERS 2022 simplified four-strata risk assessment model in adult patients with World Health…
- Trial name
- INVEXUS-PAH (NCT07266012)
- Where
- Turkey (Türkiye)
- Volunteers
- 86 people
- Sponsor
- Istanbul University - Cerrahpasa
Pulmonary Hypertension, Cardiovascular Diseases
CVD/PH and Voice Characteristics
The purpose of this study is to determine the association between patient voice signal characteristics and the presence and severity of pulmonary hypertension in patients referred for elective clinically indicated…
- Trial name
- NCT07311044
- Where
- United States
- Volunteers
- 7,000 people
- Sponsor
- Mayo Clinic
Pulmonary Hypertension
Correlation Between Estimated Right Atrial Pressure and BNP in Pulmonary HTN (CRAB-PH)
Over the past decade, advancements in therapies available for pulmonary hypertension (PH) have increased life expectancy for those who qualify and receive treatment.
- Trial name
- CRAB-PH (NCT02873039)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
Study ROR-PH-302, ADVANCE CAPACITY, was designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after…
- Trial name
- CAPACITY (NCT04084678)
- Testing
- Ralinepag
- Where
- 33 sites in United States, Argentina and 10 more
- Volunteers
- 10 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension Due to Lung Diseases
Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients
Chronic lung diseases such as pulmonary fibrosis and chronic obstructive pulmonary disease (COPD) can lead to pulmonary hypertension.
- Trial name
- NCT07498244
- Where
- Austria
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Pulmonary Hypertension
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
- Trial name
- LEVEL (NCT05983250)
- Testing
- TNX-103
- Where
- 42 sites in United States, Canada
- Volunteers
- 230 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Hypertension
Pulmonary Hypertension and Arrhythmia
Patients with pulmonary hypertension underwent (routine) Holter ECG and were screened for (malignant) arrhyhtmias. Results of Holter ECGs were correlated with clinicial and technical data (echocardiography and right heart…
- Trial name
- NCT05496504
- Testing
- Holter ECG
- Volunteers
- 222 people
- Sponsor
- Asklepios Neurological Clinic Bad Salzhausen
Hypertension, Pulmonary, Lung Diseases, Interstitial
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
A trial to evaluate the safety, tolerability, and functionality of 3P-100, in subjects with Pulmonary Hypertension (PH) accompanying Interstitial Lung Disease (ILD), PH-ILD
- Trial name
- EFS (NCT05867914)
- Testing
- Inhaled Nitric Oxide (iNO)
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Third Pole Therapeutics, Inc.
Pulmonary Hypertension
Evaluation of Novel Lung Function Parameters in Patients With Pulmonary Hypertension (PH)
Little is known about affection of small airways in patients with pulmonary hypertension as well as the ideal diagnostic approach.
- Trial name
- NCT03667794
- Testing
- body plethysmography, impulse oscillometry, multiple breath washout
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Universitätsmedizin Mannheim
Pulmonary Hypertension Due to Lung Disease (Disorder)
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3).
- Trial name
- Re-Spire (NCT07285655)
- Testing
- L606
- Where
- 44 sites in United States, Australia and 10 more
- Volunteers
- 344 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension (PH)
Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.
Previous data from our group showed reduced BMPR2 isoform A in pulmonary hypertension associated with left heart disease (PH-LHD) of valvular origin.
- Conditions
- Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension (PH), Heart Failure
- Trial name
- BREATHE-PH (NCT07537517)
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to demonstrate the efficacy of inhaled treprostinil compared to placebo in improving exercise ability as measured by change from baseline in 6-Minute Walk Distance (6MWD) following 12 weeks…
- Trial name
- PERFECT (NCT03496623)
- Testing
- Inhaled treprostinil solution
- Where
- 76 sites in United States, Argentina and 2 more
- Volunteers
- 188 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare, progressive, and potentially life-threatening disease characterized by pulmonary vascular remodeling, increased pulmonary vascular resistance, and right ventricular dysfunction.
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Trial name
- ACTION (NCT07013149)
- Testing
- Switch from Ambrisentan to Bosentan, Maintenance of Ambrisentan Therapy
- Where
- Brazil
- Volunteers
- 183 people
- Sponsor
- University of Sao Paulo General Hospital
Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
PH-HFpEF patients will receive open-label doses of levosimendan and be periodically evaluated for safety in extended use.
- Conditions
- Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction, Heart Failure With Normal Ejection Fraction
- Trial name
- NCT03624010
- Testing
- Levosimendan
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch
Understanding Delays in the Diagnosis of Pulmonary Arterial Hypertension and Rare Diseases in Brazil: A Multicenter Observational Study --- Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension
- Trial name
- PANDORA (NCT06998329)
- Testing
- There will be no intervention
- Where
- Brazil
- Volunteers
- 139 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD.
- Trial name
- NCT04691154
- Testing
- L606 inhalation suspension
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Liquidia Technologies, Inc.